Navigation Links
Jazz Pharmaceuticals Announces Development Timeline Updates
Date:6/11/2008

PALO ALTO, Calif., June 11 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced that timelines for two of its development programs have been delayed. In addition, the company will reduce its emphasis on early-stage research and development activities and implement a workforce reduction. Jazz Pharmaceuticals' sales and marketing activities will not be affected by these changes.

Clinical development will continue as previously disclosed for JZP-6, for which top-line results from the first of two Phase III clinical trials for the treatment of fibromyalgia syndrome are expected by the end of 2008. Jazz Pharmaceuticals recently announced completion of enrollment in this trial. Submission of a New Drug Application for JZP-6 is targeted for the fourth quarter of 2009. As previously disclosed, the ongoing Phase II trial of JZP-8, in development for the treatment of recurrent acute repetitive seizures, is also expected to be completed during 2008.

The company plans to complete additional pre-clinical activities prior to initiation of the Phase III program for JZP-7, its product candidate for the treatment of restless legs syndrome. As a result, the start of the Phase III program for JZP-7 will be delayed. The Phase II clinical development of JZP-4, Jazz Pharmaceuticals' product candidate for the chronic treatment of epilepsy and bipolar disorder, will be delayed to allow further formulation development work to be completed. The Phase II trial for JZP-4 and the Phase III trials for JZP-7 and JZP-8 will proceed in 2009 with additional financing or development partners for the company.

"Reducing our overall R&D spending commitments and streamlining our administrative operations gives us additional f
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...has announced that it has become a national sponso...nonprofit organizations dedicated to arthritis res... Delray Beach, FL (Vocus) November 27, ...ompany specializing in the marketing and retail di...nounced today that is has become a national sponso...
(Date:11/27/2009)..., economic burdens, study predicts , , F...eople with diabetes in the United States is expect...redicts. , That would bring the total by 2034 t...rom 23.7 million today. , , At the same time, th...e, the study also warns, rising from an estimated ...
(Date:11/27/2009)...e; announced today that Spectrum Health (Grand Rap...se orthopedic templating solution and its TraumaCa... (PRWEB) November 27, 2009 -- Voyant Health&tr...apids, Michigan) has licensed its TraumaCad Enterp...Cad Extend workflow solution, to allow its orthope...
(Date:11/27/2009)...turers who use medical load cells at the heart of ...ringing in technology partner Flintec early in the...medical manufacturers are calling in Flintec load ...s, ensuring that progress will not be constrained ...ed technology. , (PRWEB) ...
(Date:11/26/2009)...- With cold and flu season upon us, it,s more impo...l the spread of infections and avoid illness. ,...ves healthy, but to avoid transmitting illness if ...tified in infection-control), nursing director for...ital for Special Surgery (HSS) in Manhattan. ,,...
Breaking Medicine News(10 mins):Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4
...rganization said on Monday that it was setting up ...ion with the Chinese government //in fighting dise...RS, and avian influenza. A joint statement f... in Guangzhou. The center will serve as a go-betwe...
...iabetes has taken on alarming proportions in the l...lion, resulting in the loss of millions of lives, ...y the American Diabetes Association pointed out th...fected by the disease. 'Less physical activit...
... study conducted in U.S. the high sexual rating is...y explains that men are more //likely to think of ... time. The study appears in the June's issue of ‘P...versity of Connecticut and now works with the psyc...
...of prostitutes catering to World Cup fans in Germa...d to a border area in the west, said a German dise... by the weekly news magazine Focus, Norbert Brockm...women have been coerced into sex work, led to unsu...
...ses of a different and rather intriguing strain of...abama, and this has led researchers //to believe t...ny prior warning. The underlying differences...ial measures and available treatment is being mete...
...n officials in Washington say that Medicare's ne...well, filling more than three million // prescript...by an average of 50 percent. But in the Rio Grand...ho are plagued with questions and complaints fro...
Other Medicine News:Health News:A Baffling New Drug Plan In Texas Town 2
(Date:11/25/2009)....C., Nov. 25 Cempra Pharmaceutical... president and chief executive officer, will prese...nference at 8:50 a.m. EST, December 1, 2009, at Th...nandes will provide an overview of the company,s t...eatment of drug-resistant pathogens including MRSA...
(Date:11/25/2009).... and SYDNEY, Nov. 25 He...HIN), a leading innovator and provider of less inv...es revolutionizing the treatment of advanced heart...make an investor presentation at the 21st Annual P... on Wednesday, December 2, 2009. The conference is...
(Date:11/24/2009)...v. 24 Endologix, Inc. (N...eatments for aortic disorders, announced today tha...l proceedings in, the patent infringement lawsuit ...The motion was filed in the United States District...as requested that the stay remain in effect while ...
Breaking Medicine Technology:HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City 2Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2ConvaTec Launches Versiva 28R 29 XC 28R 29 Campaign and Best Practice Statement 53943 1ConvaTec Launches Versiva 28R 29 XC 28R 29 Campaign and Best Practice Statement 53943 2ConvaTec Launches Versiva 28R 29 XC 28R 29 Campaign and Best Practice Statement 53943 3ConvaTec Launches Versiva 28R 29 XC 28R 29 Campaign and Best Practice Statement 53943 4ConvaTec Launches Versiva 28R 29 XC 28R 29 Campaign and Best Practice Statement 53943 5Slide Into Debt Could Bring Wider Waistline 53941 1Slide Into Debt Could Bring Wider Waistline 53941 2FDA Approves New 3000 IU Vial Size for Kogenate 28R 29 FS antihemophilic factor 28recombinant 29 53939 1FDA Approves New 3000 IU Vial Size for Kogenate 28R 29 FS antihemophilic factor 28recombinant 29 53939 2FDA Approves New 3000 IU Vial Size for Kogenate 28R 29 FS antihemophilic factor 28recombinant 29 53939 3FDA Approves New 3000 IU Vial Size for Kogenate 28R 29 FS antihemophilic factor 28recombinant 29 53939 4
...al Software Advice website ( www.softwareadvice.co...ical software buyers with the right technology for...l software is booming, but the software vendor lan...n Fornes, founder & Chief Executive Officer of...o the market by matching physicians with the right...
...gh,Corporation (NYSE: SGP ) today reported on new... fast-dissolving, sublingual tablet being,develope...ve than placebo,and well tolerated in treating pat... results, asenapine 5 mg twice daily and 10 mg twi...an placebo at improving,patient Positive and Negat...
Other Medicine Technology:Physicians Will Benefit from Medical Software Advice Website 2New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia 2New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia 3New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia 4
...asound system provides dedicated and complete card... ultrasound system offering exceptional image qual...nd spatial resolution everything you associate wi...Designed specifically for busy cardiovascular spec...
AngioSpeed VH
Atlantis SR Plus Catheter
CardioGen-82®
Medicine Products: